Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ISO 8637-12:2017 – Cardiovascular Implants and Extracorporeal Systems: Requirements for Haemodialysers, Haemofilters and Haemoconcentrators
A Comprehensive Technical Overview of Safety, Performance and Compliance for Extracorporeal Blood Purification Devices
Scope and Field of Application
ISO 8637-12:2017 is a comprehensive international standard that specifies safety, performance, and quality requirements for haemodialysers, haemofilters, and haemoconcentrators used in extracorporeal blood purification therapies. It covers the design, material selection, manufacturing, biocompatibility, sterility, packaging, and labelling of these devices. The standard is applicable to devices intended for single-use or multiple-use (where reuse processing is specified) and addresses both the haemodialyser/filter/harmoconcentrator itself and the associated extracorporeal blood circuit. It serves as a harmonized reference for regulatory approvals in many national and regional jurisdictions, including the European Medical Device Regulation (MDR) and the U.S. Food and Drug Administration (FDA) 510(k) submissions.
The standard replaces earlier editions (ISO 8637:2004) and parts 1 and 2 of the series, consolidating key performance, biocompatibility, and mechanical requirements in a single part. It is intended for manufacturers, testing laboratories, and regulatory bodies involved in the design, validation, and certification of these critical medical devices.
Tip: Manufacturers should review the transition timelines for national adoptions of ISO 8637-12:2017, as some markets may still accept earlier versions during a coexistence period.
Technical Requirements
Design and Construction
ISO 8637-12:2017 mandates design verification for all fluid-contacting components. The blood pathway must be smooth, without sharp edges or irregularities that could cause haemolysis or thrombogenicity. Connector ports must conform to ISO 594 series or ISO 80369 (for small-bore connectors) to ensure universal compatibility with associated blood lines. The housing and potting materials (typically polyurethane or silicone) must be non-cytotoxic and resistant to sterilisation processes.
Biocompatibility and Material Safety
The standard requires compliance with ISO 10993 series for biological evaluation. Tests must include cytotoxicity, sensitisation, irritation, acute systemic toxicity, and haemocompatibility (haemolysis, thrombogenicity, complement activation). Additionally, specific requirements for pyrogenicity (bacterial endotoxin test) are outlined, with threshold limits not exceeding 0.5 EU/mL based on the patient-extractable volume.
Performance Parameters
Key technical parameters are summarised in the table below:
| Parameter | Requirement / Test Method | Limits / Typical Values |
|---|---|---|
| Ultrafiltration coefficient (UFC) | Measured at 37 °C with bovine blood at defined haematocrit and protein concentration | Manufacturer-specified ± 15 % |
| Urea clearance (Kurea) | In vitro test at 300 mL/min blood flow, 500 mL/min dialysate flow | ≥ 80 % of labelled value |
| Creatinine clearance | Same test conditions as urea clearance | ≥ 85 % of labelled value |
| Effective membrane surface area | Measured by geometric method or tracer method | Tolerance: ± 5 % of nominal |
| Blood compartment pressure drop | At QB = 200 mL/min, QD = 0 | ≤ 30 mmHg (typical) |
| Gross leak test (internal pressure) | Pressurised at 200 kPa for 1 minute | No visible leaks |
| Sterility assurance level (SAL) | ISO 11135 (EO) or ISO 11137 (gamma) validation | SAL ≤ 10−6 |
Success criterion: Meeting UFC and clearance tolerances ensures consistent therapy delivery; manufacturers should use robust design-of-experiments to optimise fibre bundle packing and membrane permeability.
Sterilisation and Packaging
Devices must be sterilised by a validated process (ethylene oxide, gamma irradiation, or steam). The packaging shall maintain sterility and device integrity throughout the intended storage period. Package integrity testing (e.g., dye ingress, bubble leak) is required per ASTM F1929 or equivalent. The standard also calls for accelerated and real-time ageing studies to establish shelf life.
Implementation Highlights
Adopting ISO 8637-12:2017 requires a systematic approach to design control and risk management (ISO 14971). Key implementation steps include:
- Gap analysis against the revised performance and labelling clauses, particularly regarding biocompatibility documentation and UFC tolerance.
- Redesign of test fixtures for in vitro clearance and UFC measurement, ensuring traceability to reference methods described in the standard.
- Update of technical files to include rationales for design parameters, test protocols, and acceptance criteria.
- Cross-validation with existing quality management systems (ISO 13485) and integration of the standard’s specific requirements (e.g., bioburden monitoring for non-sterile devices intended for reuse).
Manufacturers should also consider the implications for clinical evaluation data, as the standard may influence the level of evidence required for equivalence claims under MDR or FDA expectations.
Warning: Pay special attention to the updated requirements for connector ports – devices using non-standard connectors will need to redesign or provide adapters; non-compliance may block market access.
Compliance and Certification Notes
Compliance with ISO 8637-12:2017 is typically demonstrated by a combination of design documentation, test reports, and quality system records. Notified bodies or regulatory authorities may request:
- Detailed biocompatibility evaluation reports covering all direct and indirect blood-contacting materials.
- Performance test data from independent laboratories (e.g., test houses accredited to ISO 17025).
- Sterilisation validation reports, including dose audit and routine release tests.
- Risk management file with specific hazards identification (e.g., leaks, material degradation, dose rate variations).
Early dialogue with the reviewing body (e.g., through a pre-submission meeting in the US) is recommended to clarify acceptance criteria for novel designs.
Critical compliance point: Inadequate validation of the UF coefficient tolerance can lead to delays in certification. Ensure that the measurement uncertainty of test equipment is accounted for and that the production variability is captured in the design margin.
Frequently Asked Questions
Q: Does ISO 8637-12:2017 replace both ISO 8637-1 and ISO 8637-2?
A: Yes. This edition consolidates the requirements formerly split into two parts. Manufacturers previously certifying to ISO 8637-1:2017 and ISO 8637-2:2017 should re-evaluate their technical files against the unified standard and adjust where new or stricter clauses apply.
A: Yes. This edition consolidates the requirements formerly split into two parts. Manufacturers previously certifying to ISO 8637-1:2017 and ISO 8637-2:2017 should re-evaluate their technical files against the unified standard and adjust where new or stricter clauses apply.
Q: Are there any transition periods for compliance?
A: That depends on local regulations. In the European Union, for instance, the transition to the new standard is linked to the publication of its reference in the Official Journal. As of 2025, many authorities expect full adoption, but manufacturers should verify acceptance dates with their notified body.
A: That depends on local regulations. In the European Union, for instance, the transition to the new standard is linked to the publication of its reference in the Official Journal. As of 2025, many authorities expect full adoption, but manufacturers should verify acceptance dates with their notified body.
Q: How does the standard address devices intended for multiple reuses?
A: ISO 8637-12:2017 includes requirements for residual bioburden, cleaning, and reprocessing validation. The device’s labelling must clearly indicate up to how many reuse cycles it has been validated, and the manufacturer must provide instructions for safe reprocessing.
A: ISO 8637-12:2017 includes requirements for residual bioburden, cleaning, and reprocessing validation. The device’s labelling must clearly indicate up to how many reuse cycles it has been validated, and the manufacturer must provide instructions for safe reprocessing.
Q: Can additive manufacturing technologies be used for components under this standard?
A: Yes, provided that the materials and final components meet the same biocompatibility, mechanical, and dimensional requirements. The manufacturer must demonstrate equivalency through additional testing, especially for porosity, surface finish, and potential extractables.
A: Yes, provided that the materials and final components meet the same biocompatibility, mechanical, and dimensional requirements. The manufacturer must demonstrate equivalency through additional testing, especially for porosity, surface finish, and potential extractables.